Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update Savara (Nasdaq: SVRA) reported that the FDA accepted the MOLBREEVI BLA with Priority Review and set a PDUFA date of August 22, 2026. MAAs were submitted to the EMA and MHRA. As of December 31, 2025, cash and short-term investments were $235.7M, with access to up to $150M of non-dilutive capital upon FDA approval.Financials: Q4 net loss was $32.2M and FY2025 net loss was $118.8M; R&D was $81.4M and G&A increased to $42.1M.

#SVRA Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/SVRA/savara-reports...

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Savara (Nasdaq: SVRA) received a Day 74 letter from the FDA indicating no Advisory Committee is planned for the MOLBREEVI BLA and the review continues toward a PDUFA target action date of August 22, 2026. The company submitted an MAA to the EMA for autoimmune PAP and remains on track to submit to the UK MHRA by end of Q1 2026. MOLBREEVI holds FDA Fast Track, Breakthrough Therapy and Orphan Drug designations, EMA Orphan Drug designation, and MHRA Innovation Passport and PIM designations. The update summarizes regulatory progress and timelines for potential approvals in the U.S., EU and UK.

#SVRA Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

www.stocktitan.net/news/SVRA/savara-provide...

Savara Announces Participation in 2026 Citizens Life Sciences Conference Savara (Nasdaq: SVRA) said members of management will appear in a fireside chat at the 2026 Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 10:10 AM ET in Miami, FL. The session will be webcast live with a replay archived for 90 days on the company website.

#SVRA Savara Announces Participation in 2026 Citizens Life Sciences Conference

www.stocktitan.net/news/SVRA/savara-announc...

RT @RacingAmerica: Greatness never retires!

Bill Elliott takes the podium in the first sprint race at Sebring. #legend #SVRA

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* Savara (Nasdaq: SVRA) said the European Patent Office intends to grant a patent for the liquid formulation of MOLBREEVI, which would provide protection in Europe through March 2041. The company also noted a separate European patent already granted for the drug-device combination of MOLBREEVI delivered via PARI’s eFlow® nebulizer, covering protection through March 2043.Savara said MOLBREEVI would be eligible for 10 years of Orphan Drug exclusivity in the EU upon approval. The company expects to resubmit the MOLBREEVI BLA to the FDA in December 2025 and to file MAA submissions in the EU and U.K. by the end of 1Q 2026. MOLBREEVI holds FDA Fast Track and Breakthrough Therapy designations, FDA and EMA Orphan Drug designations, and MHRA IP and PIM designations for autoimmune PAP.

#SVRA Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

www.stocktitan.net/news/SVRA/savara-announc...

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System Savara (Nasdaq: SVRA) and PARI were granted European Patent No. 4 496 611 covering the drug-device combination of MOLBREEVI delivered via the eFlow® Nebulizer System.The patent covers the combination through March 2043. The company cited a 10-year Orphan Drug regulatory exclusivity upon EU approval and noted an exclusive license with PARI. Savara plans a December resubmission of the MOLBREEVI BLA in the U.S. and 1Q 2026 MAA submissions in Europe and the U.K. Regulatory designations include FDA Fast Track, Breakthrough Therapy, FDA and EMA Orphan Drug, and the UK’s Innovation Passport and PIM designations. The eFlow system is planned for commercial launch as the Vespera Nebulizer System if approved.

#SVRA Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

www.stocktitan.net/news/SVRA/savara-and-par...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SVRA, #DOCN, #UPWK, #ON, #NVAX

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #VLO 22.5x
2. #SVRA 6.2x
3. #DOCN 5.9x
4. #TOST 5.0x
5. #WMT 4.7x

#OptionFlow #OptionsTrading #Trading

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update Savara (NASDAQ: SVRA) reported third quarter 2025 results and a business update on November 12, 2025. The company said it is on track to resubmit the MOLBREEVI BLA for autoimmune pulmonary alveolar proteinosis in December 2025 and will request priority review. Savara expects to submit Marketing Authorization Applications to the EMA and MHRA in 1Q 2026. Recent financings strengthened the balance sheet: a public equity offering that added ~$140M and a ~$75M royalty funding agreement; cash, cash equivalents and short-term investments were ~$124.4M as of September 30, 2025. Q3 net loss was $29.6M (loss per share $(0.14)); research and development and commercial preparations continued.

#SVRA Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/SVRA/savara-reports...

Levi & Korsinsky Files Class Action Lawsuit for Savara Inc. Investors Amid Allegations of Fraud In a significant move, Levi & Korsinsky, LLP has initiated a class action lawsuit for shareholders of Savara Inc., alleging securities fraud and misrepresentation.

Levi & Korsinsky Files Class Action Lawsuit for Savara Inc. Investors Amid Allegations of Fraud #USA #New_York #Levi_&_Korsinsky #Savara_Inc. #SVRA

Class Action Lawsuit Filed Against Savara Inc. Over Securities Violations Investors in Savara Inc. are urged to join a class action suit for alleged securities law violations. Join the DJS Law Group for possible recovery.

Class Action Lawsuit Filed Against Savara Inc. Over Securities Violations #USA #Los_Angeles #DJS_Law_Group #Savara_Inc. #SVRA

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 7,142,857 shares of common stock...

#SVRA Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

www.stocktitan.net/news/SVRA/savara-announc...

#SVRA Savara Announces Proposed Public Offering

www.stocktitan.net/news/SVRA/savara-announc...

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Savara (NASDAQ: SVRA) announced a $75 million royalty funding agreement with RTW Investments to support a potential U.S. launch of MOLBREEVI for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), contingent on FDA approval and customary closing conditions.The financing is non-dilutive, becomes available upon approval, and pays RTW a tiered single‑digit percentage of U.S. annual net sales for MOLBREEVI subject to a cap. Savara plans to resubmit the MOLBREEVI BLA in December 2025 and cites pivotal IMPALA-2 results as supporting commercial potential.

#SVRA Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

www.stocktitan.net/news/SVRA/savara-announc...

Levi & Korsinsky Alerts Savara Inc. Investors of Critical Class Action Suit Deadline in 2025 Levi & Korsinsky LLP informs Savara Inc. investors about a significant class action lawsuit with a lead plaintiff deadline. Act before November 7, 2025.

Levi & Korsinsky Alerts Savara Inc. Investors of Critical Class Action Suit Deadline in 2025 #United_States #New_York #Levi_Korsinsky #Savara_Inc #SVRA

Savara Inc. Faces Lawsuit Over Securities Law Violations Amid Shareholder Concerns Savara Inc. is under scrutiny as shareholders file a lawsuit regarding potential securities law violations linked to the company's practices. Interested parties are urged to reach out.

Savara Inc. Faces Lawsuit Over Securities Law Violations Amid Shareholder Concerns #USA #New_York #Gross_Law_Firm #Savara_Inc. #SVRA

Savara Inc Faces Class Action Lawsuit for Securities Violations – What You Need to Know Investors in Savara Inc. may be affected by a class action lawsuit due to alleged securities law violations. Understand your rights here.

Savara Inc Faces Class Action Lawsuit for Securities Violations – What You Need to Know #United_States #DJS_Law_Group #Eastchester #Savara_Inc #SVRA

Investors Encouraged to Join Savara Inc. Securities Fraud Class Action Lawsuit Savara Inc. investors are urged to join a securities fraud class action lawsuit. Important deadlines and details about the case are provided.

Investors Encouraged to Join Savara Inc. Securities Fraud Class Action Lawsuit #USA #New_York #Rosen_Law_Firm #Savara_Inc. #SVRA

Legal Action Alert: Savara Inc. Faces Securities Law Class Action Lawsuit Savara Inc. is currently embroiled in a class action lawsuit for alleged securities law violations. Investors affected between March 7, 2024, and May 23, 2025, should contact DJS Law Group.

Legal Action Alert: Savara Inc. Faces Securities Law Class Action Lawsuit #United_States #DJS_Law_Group #Eastchester #Savara_Inc #SVRA

Savara Announces Chief Medical Officer (CMO) Transition Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced Yasmine Wasfi, M.D., Ph.D., FCCP has been promoted to CMO, effective immediately. She succeeds Ray Pratt, M.D., FACP who will transition from his current role to Senior Medical Advisor. Wasfi will report directly to the Company’ s Chair and Chief Executive...

#SVRA Savara Announces Chief Medical Officer (CMO) Transition

www.stocktitan.net/news/SVRA/savara-announc...

Investors Uniting Against Savara Inc. in Securities Law Class Action Lawsuit A class action lawsuit has been filed against Savara Inc. for alleged violations of securities laws. Investors are encouraged to join the case.

Investors Uniting Against Savara Inc. in Securities Law Class Action Lawsuit #USA #DJS_Law_Group #Eastchester #Savara_Inc. #SVRA

Savara Inc. Faces Class Action Lawsuit for Securities Fraud - Details Inside Savara Inc. is currently embroiled in a class action lawsuit over alleged securities fraud impacting investors. Learn more about the case.

Savara Inc. Faces Class Action Lawsuit for Securities Fraud - Details Inside #USA #New_York #Levi_&_Korsinsky #Savara_Inc. #SVRA

Important Notice for Savara Inc. Shareholders: Class Action Details Savara Inc. shareholders who suffered losses are encouraged to participate in a class action. The Gross Law Firm is leading the case, urging timely registration.

Important Notice for Savara Inc. Shareholders: Class Action Details #United_States #New_York #The_Gross_Law_Firm #Savara_Inc #SVRA

Savara Inc. Faces Class Action Lawsuit for Alleged Securities Violations in 2025 Savara Inc. is under scrutiny with a class action lawsuit for securities law violations. Investors encouraged to contact the DJS Law Group for details.

Savara Inc. Faces Class Action Lawsuit for Alleged Securities Violations in 2025 #United_States #DJS_Law_Group #Eastchester #Savara_Inc #SVRA

Investors Alert: Class Action Lawsuit Filed Against Savara Inc. Over Securities Law Violations A class action lawsuit is underway against Savara Inc. for securities law violations. Investors are encouraged to join and reclaim losses. Deadline: Nov 10, 2025.

Investors Alert: Class Action Lawsuit Filed Against Savara Inc. Over Securities Law Violations #United_States #Class_Action #Los_Angeles #Savara_Inc. #SVRA

Savara Inc. Investors: Important Class Action Lawsuit Timeline and Leads Savara Inc. shareholders: Don't miss the lead plaintiff deadline for the class action lawsuit. Know your rights and timeline important for recovery.

Savara Inc. Investors: Important Class Action Lawsuit Timeline and Leads #United_States #New_York #Gross_Law_Firm #Savara_Inc #SVRA

Shareholders of Savara Inc. Face Class Action Lawsuit Over Securities Fraud Allegations Savara Inc. investors are notified of a class action lawsuit regarding alleged securities fraud. Shareholders have until November 7 to act.

Shareholders of Savara Inc. Face Class Action Lawsuit Over Securities Fraud Allegations #United_States #New_York #Class_Action #Savara_Inc. #SVRA

Savara Inc. Faces Class Action for Securities Law Breach - What Investors Should Know A class action lawsuit has been initiated against Savara Inc. concerning serious securities law violations, urging investors to explore their legal rights.

Savara Inc. Faces Class Action for Securities Law Breach - What Investors Should Know #USA #Los_Angeles #Securities_Law #Savara_Inc #SVRA

Investors of Savara Inc. Get Chance to Lead Class Action Lawsuit Over Misleading Statements Savara Inc. investors suffering losses are invited to lead a class action lawsuit over unreported issues related to their drug application, raising possibilities of securities fraud.

Investors of Savara Inc. Get Chance to Lead Class Action Lawsuit Over Misleading Statements #USA #Los_Angeles #Frank_R._Cruz #Savara_Inc #SVRA

Investors Urged to Join Class Action Against Savara Inc. Following Misleading Information Investors who faced financial losses in Savara Inc. are encouraged to connect with Robbins LLP about a class action lawsuit concerning misleading statements.

Investors Urged to Join Class Action Against Savara Inc. Following Misleading Information #USA #San_Diego #Robbins_LLP #Savara_Inc #SVRA